MGNX

MacroGenics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.60
52-Week Range: $1.29 – $5.08
Market Cap: $228.05M
P/E (TTM): —
EPS (TTM): -1.70
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 5.31
PEG Ratio: —
Return on Equity: -225.85%
Return on Assets: -8.05%
Gross Margin: -0.74%
Operating Margin: -42.19%
Profit Margin: -8.33%
Current Ratio: 2.96
Debt/Equity: 0.82
Total Debt: $35.09M
Free Cash Flow: $-69.41M
Revenue Growth: 378.00%
Earnings Growth: —
Enterprise Value: $89.83M

MGNX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$150.02M	$58.75M	$149.96M	$149.50M
Cost of Revenue	$7.38M	$8.22M	$12.30M	$36.01M
Gross Profit	$142.63M	$50.53M	$137.66M	$113.49M
Research & Development	$207.03M	$166.58M	$177.19M	$147.17M
Selling, General & Admin	$58.95M	$52.19M	$71.05M	$39.16M
Operating Expenses	$264.05M	$218.77M	$248.24M	$186.33M
Operating Income	-$121.42M	-$168.24M	-$110.58M	-$72.84M
EBITDA	-$107.89M	$2.02M	-$57.37M	-$59.61M
Pretax Income	-$119.76M	-$9.06M	-$66.02M	-$75.29M
Income Tax	$0.00	$0.00	$944.00K	-$672.00K
Net Income	-$119.76M	-$9.06M	-$66.97M	-$74.62M
Diluted EPS	-1.95	-0.15	-1.07	-1.18
Diluted Shares	61.43M	61.93M	62.62M	63.16M

MGNX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$108.88M	$100.96M	$182.84M	$57.22M
Receivables	$56.22M	$10.37M	$4.31M	$13.37M
Inventory	$1.45M	$1.22M	$0.00	$7.91M
Current Assets	$222.18M	$251.34M	$217.49M	$219.94M
Total Assets	$280.47M	$298.42M	$261.65M	$256.85M
Current Liabilities	$48.61M	$56.11M	$55.53M	$43.12M
Total Debt	$34.83M	$33.97M	$37.46M	$36.76M
Total Liabilities	$138.46M	$145.81M	$145.60M	$201.25M
Retained Earnings	-$1.09B	-$1.10B	-$1.17B	-$1.24B
Shareholders' Equity	$142.01M	$152.61M	$116.06M	$55.59M
Working Capital	$173.57M	$195.23M	$161.96M	$176.83M

MGNX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$86.96M	-$78.20M	-$68.37M	-$81.04M
Capital Expenditure	-$3.62M	-$1.76M	-$3.71M	-$1.91M
Free Cash Flow	-$90.58M	-$79.97M	-$72.08M	-$82.95M
Depreciation & Amortisation	$11.87M	$9.64M	$7.54M	$7.17M
Stock-Based Compensation	$20.44M	$18.37M	$29.44M	$14.29M
Investing Cash Flow	$70.72M	-$80.08M	$149.30M	-$114.10M
Financing Cash Flow	$1.66M	$150.36M	$960.00K	$69.51M
Net Change in Cash	-$14.59M	-$7.93M	$81.88M	-$125.62M

MGNX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$13.19M	$6.87M	$72.84M	$41.23M	$20.77M	$32.83M
Cost of Revenue	$5.40M	$8.91M	$11.59M	$10.12M	$9.53M	—
Gross Profit	$7.79M	$13.34M	$61.25M	$31.11M	$11.24M	—
Research & Development	$39.70M	$40.79M	$32.71M	$33.97M	$34.97M	$38.78M
Selling, General & Admin	$10.72M	$9.30M	$9.90M	$9.23M	$9.71M	$7.90M
Operating Expenses	$50.42M	$50.09M	$42.61M	$43.21M	$44.68M	$46.68M
Operating Income	-$42.62M	-$43.22M	$18.64M	-$12.10M	-$33.44M	-$13.85M
EBITDA	-$39.17M	-$39.90M	$21.95M	-$8.96M	-$30.20M	-$64.54M
Pretax Income	-$41.04M	-$42.61M	$16.82M	-$14.93M	-$36.77M	-$69.64M
Income Tax	—	$105.00K	$0.00	-$777.00K	—	$0.00
Net Income	-$41.04M	-$36.25M	$16.82M	-$14.15M	-$36.77M	$19.52M
Diluted EPS	-0.65	-0.57	0.27	—	-0.58	0.31
Diluted Shares	62.97M	63.14M	63.28M	—	63.45M	63.59M

MGNX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$145.57M	$130.69M	$80.13M	$57.22M	$66.52M	$113.91M
Receivables	$10.54M	$12.53M	$69.23M	$13.37M	$10.43M	$144.17M
Inventory	$9.43M	$9.28M	$8.75M	$7.91M	$9.50M	—
Current Assets	$182.09M	$204.94M	$232.09M	$219.94M	$182.52M	$321.69M
Total Assets	$224.56M	$245.42M	$270.76M	$256.85M	$217.87M	$345.41M
Current Liabilities	$55.44M	$39.00M	$44.47M	$43.12M	$95.94M	$108.81M
Total Debt	$37.47M	$37.25M	$37.01M	$36.76M	$36.51M	$35.09M
Total Liabilities	$145.45M	$198.80M	$203.76M	$201.25M	$196.68M	$302.54M
Retained Earnings	-$1.21B	-$1.25B	-$1.23B	-$1.24B	-$1.28B	-$1.26B
Shareholders' Equity	$79.12M	$46.62M	$67.00M	$55.59M	$21.20M	$42.87M
Working Capital	$126.65M	$165.94M	$187.62M	$176.83M	$86.58M	$212.87M

MGNX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$46.89M	-$46.98M	-$30.19M	$43.02M	-$35.81M	-$40.75M
Capital Expenditure	-$529.00K	-$715.00K	-$426.00K	-$244.00K	-$344.00K	-$806.00K
Free Cash Flow	-$47.42M	-$47.70M	-$30.61M	$42.78M	-$36.16M	-$41.55M
Depreciation & Amortisation	$1.77M	$1.91M	$1.79M	$1.71M	$1.69M	$708.00K
Stock-Based Compensation	$4.39M	$3.69M	$3.55M	$2.66M	$2.65M	$1.97M
Investing Cash Flow	$9.90M	-$37.64M	-$20.37M	-$65.99M	$45.32M	$27.96M
Financing Cash Flow	-$282.00K	$69.74M	$0.00	$57.00K	-$207.00K	$60.17M
Net Change in Cash	-$37.27M	-$14.88M	-$50.56M	-$22.91M	$9.30M	$47.39M

Market Snapshot

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies. The company develops innovative antibody-based therapeutics using proprietary technology platforms to create treatments for cancer and autoimmune diseases, with multiple product candidates in clinical development.